Imfinzi

E505480

immune checkpoint inhibitor pharmaceutical drug prescription medicine

Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.

Try in SPARQL Jump to: Surface forms Statements Referenced by

Observed surface forms (1)

Surface form	Occurrences
durvalumab	1

Statements (47)

Predicate	Object
instanceOf	immune checkpoint inhibitor ⓘ pharmaceutical drug ⓘ prescription medicine ⓘ
administeredInCombinationWith	chemotherapy ⓘ etoposide ⓘ platinum-based chemotherapy ⓘ
approvalBy	European Medicines Agency NERFINISHED ⓘ U.S. Food and Drug Administration NERFINISHED ⓘ
belongsToRegimenType	first-line therapy for certain lung cancers ⓘ maintenance therapy ⓘ
belongsToTherapeuticArea	immuno-oncology ⓘ oncology ⓘ
developedBy	AstraZeneca NERFINISHED ⓘ AstraZeneca plc NERFINISHED ⓘ
hasATCClass	L01FF03 ⓘ
hasDosageForm	solution for infusion ⓘ
hasDrugClass	PD-L1 inhibitor ⓘ
hasGenericName	durvalumab NERFINISHED ⓘ
hasINN	durvalumab NERFINISHED ⓘ
hasMolecularTarget	B7-H1 NERFINISHED ⓘ CD274 NERFINISHED ⓘ
indicatedFor	bladder cancer ⓘ extensive-stage small cell lung cancer ⓘ non-small cell lung cancer ⓘ previously treated advanced urothelial carcinoma ⓘ small cell lung cancer ⓘ unresectable stage III non-small cell lung cancer ⓘ urothelial carcinoma ⓘ
indicatedSetting	locally advanced cancer ⓘ metastatic cancer ⓘ
isBiologic	true ⓘ
isPrescriptionOnly	true ⓘ
isTypeOf	IgG1 kappa monoclonal antibody ⓘ human monoclonal antibody ⓘ
mechanismOfAction	blocks interaction between PD-L1 and PD-1 receptors ⓘ enhances T-cell mediated immune response against tumor cells ⓘ
pharmacologicalEffect	anti-tumor immune activation ⓘ immune checkpoint blockade ⓘ
regulatoryStatus	EMA-approved ⓘ FDA-approved ⓘ
routeOfAdministration	intravenous infusion ⓘ
targets	PD-L1 NERFINISHED ⓘ programmed death-ligand 1 ⓘ
therapeuticIntent	delay disease progression ⓘ prolong overall survival ⓘ
usedFor	cancer immunotherapy ⓘ oncology treatment ⓘ

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.

AstraZeneca → notableProduct → Imfinzi ⓘ

programmed death-ligand 1 → targetOfDrug → Imfinzi ⓘ

this entity surface form: durvalumab